STORM Therapeutics secures $56 Million Series C financing and doses first patient in Phase 2 sarcoma trial of STC‑15
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications
First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation
16 April 2026, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announced a successful $56 million Series C financing.
